Pharmalink AB has entered into a service contract with GP Pharm for the manufacture of Pharmalink’s Busulipo, which is being developed as a conditioning agent for use prior to bone marrow transplantation. The agreement covers the manufacture of Busulipo from clinical to commercial quantities. Financial terms were not disclosed. GP Pharm focuses on injectable oncology products and also offers contract development and manufacturing services.   Johan Häggblad, managing director of Pharmalink, said,...